We are live on !
Find out more
Andreas Halvorsen Viking Global Investors
AUM
$35.1B
Turnover
49.55%
1-Year Est. Return
21.36%
Andreas Halvorsen is the founder of Viking Global Investors, another prominent firm with roots in Julian Robertson’s Tiger Management. Viking is known for fundamental long/short equity investing and a large, research-intensive platform. Its public filings are widely monitored for institutional-quality growth and cyclical equity ideas.
This Fund
S&P 500
This Quarter Est. Return
+12.79%
1 Year Est. Return
+21.36%
3 Year Est. Return
+97.07%
5 Year Est. Return
+98.11%
10 Year Est. Return
+504%
AUM
$35.1B
AUM Growth
-$669M
(-1.9%)
Cap. Flow
-$3.53B
Cap. Flow % of AUM
Cap. Flow %
-10.07%
Top 10 Holdings %
Top 10 Hldgs %
35.67%
Holding
111
New
34
Increased
18
Reduced
28
Closed
21
Avg Time Held
1.1
years
Top 10 Avg Time Held
0.6
years
Top 20 Avg Time Held
0.8
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Ferrari
RACE
|
+$767M |
| 2 |
MSCI
MSCI
|
+$677M |
| 3 |
Amazon
AMZN
|
+$629M |
| 4 |
Union Pacific
UNP
|
+$538M |
| 5 |
Meta Platforms (Facebook)
META
|
+$492M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$912M |
| 2 |
Tesla
TSLA
|
+$774M |
| 3 |
CSX Corp
CSX
|
+$767M |
| 4 |
Alphabet (Google) Class A
GOOGL
|
+$689M |
| 5 |
PNC Financial Services
PNC
|
+$630M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 20.09% |
| 2 | Consumer Discretionary | 17.6% |
| 3 | Healthcare | 16.02% |
| 4 | Industrials | 14.5% |
| 5 | Technology | 11.16% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
51
ATI
ATI
$21.7B
| $227M | 0.65% |
1,153,880
-2,178,963
| -65% | -$369M |
2026 Q1
1 quarter
|
|
52
Roivant Sciences
ROIV
$27.4B
| $222M | 0.63% |
6,271,467
-380,981
| -6% | -$11.3M |
2021 Q4
18 quarters
|
|
53
SpaceX
SPCX
$1.97T
| $205M | 0.58% |
+1,200,000
| New | +$204M |
2026 Q2
0 quarters
|
|
54
Amer Sports
AS
$17.1B
| $201M | 0.57% |
5,954,351
-1,316,125
| -18% | -$46.1M |
2025 Q1
5 quarters
|
|
55
Veradermics Inc
MANE
$5.86B
| $192M | 0.55% |
1,561,494
-129,061
| -8% | -$12.1M |
2026 Q1
1 quarter
|
|
56
Medline Inc
MDLN
$30.3B
| $191M | 0.54% |
4,841,080
-6,592,912
| -58% | -$266M |
2025 Q4
2 quarters
|
|
57
BCE
BCE
$19.2B
| $181M | 0.51% |
+8,383,278
| New | +$201M |
2026 Q2
0 quarters
|
|
58
US Foods
USFD
$22.2B
| $177M | 0.51% |
+1,734,346
| New | +$155M |
2026 Q2
0 quarters
|
|
59
Oruka Therapeutics
ORKA
$5.39B
| $143M | 0.41% |
1,503,478
-1,163,212
| -44% | -$77.5M |
2025 Q3
3 quarters
|
|
60
NewAmsterdam Pharma
NAMS
$2.6B
| $142M | 0.41% |
4,203,567
| – | – |
2022 Q4
14 quarters
|
|
61
Sionna Therapeutics
SION
$169M
| $141M | 0.4% |
3,195,181
| – | – |
2025 Q1
5 quarters
|
|
62
Chubb
CB
$140B
| $129M | 0.37% |
377,312
-917,699
| -71% | -$299M |
2025 Q4
2 quarters
|
|
63
Pharvaris
PHVS
$2.12B
| $126M | 0.36% |
3,653,310
| – | – |
2021 Q1
21 quarters
|
|
64
UBS Group
UBS
$143B
| $121M | 0.34% |
+2,435,805
| New | +$111M |
2026 Q2
0 quarters
|
|
65
BrightSpring Health Services
BTSG
$12B
| $113M | 0.32% |
+1,618,237
| New | +$89.9M |
2026 Q2
0 quarters
|
|
66
Inhibrx
INBX
$1.39B
| $106M | 0.3% |
1,123,929
-313,776
| -22% | -$31.4M |
2024 Q2
8 quarters
|
|
67
Natera
NTRA
$56.5B
| $106M | 0.3% |
+390,694
| New | +$83.3M |
2026 Q2
0 quarters
|
|
68
Deutsche Bank
DB
$59.2B
| $85M | 0.24% |
+2,510,554
| New | +$81.4M |
2026 Q2
0 quarters
|
|
69
Capital One
COF
$125B
| $77.8M | 0.22% |
387,815
-1,224,559
| -76% | -$234M |
2025 Q1
5 quarters
|
|
70
Corebridge Financial
CRBG
$15.6B
| $76.7M | 0.22% |
+2,679,371
| New | +$72.5M |
2026 Q2
0 quarters
|
|
71
SolarEdge
SEDG
$2.01B
| $63.6M | 0.18% |
+1,088,469
| New | +$57M |
2026 Q2
0 quarters
|
|
|
DMRA
72
Damora Therapeutics
DMRA
$1.34B
| $60.1M | 0.17% |
2,311,082
| – | – |
2026 Q1
1 quarter
|
|
73
Oric Pharmaceuticals
ORIC
$1.42B
| $55.5M | 0.16% |
5,126,762
-697,771
| -12% | -$6.33M |
2024 Q1
9 quarters
|
|
74
Bruker
BRKR
$8.62B
| $53.8M | 0.15% |
+893,491
| New | +$41.7M |
2026 Q2
0 quarters
|
|
75
Standard BioTools
LAB
$256M
| $48.3M | 0.14% |
58,651,170
| – | – |
2024 Q1
9 quarters
|
|
Similar funds
Andreas Halvorsen's Q2 2026 Portfolio in Review
As of Q2 2026, Andreas Halvorsen held 111 positions worth $35.1B, down 1.9% from $35.7B the previous quarter. Its ten largest holdings account for 36% of the portfolio.
Andreas Halvorsen withdrew a net $3.53B in Q2 2026, closing 21 positions and reducing 28 holdings. Its most notable exit was Apple, an estimated $912M position sold in full.
By sector, the portfolio is most concentrated in Financials at 20% of assets, down from 21% a quarter earlier, followed by Consumer Discretionary and Healthcare.
Against the trend, Andreas Halvorsen opened a new position in Ferrari worth $817M.
- Andreas Halvorsen's largest Q2 2026 buy was Ferrari: 2,204,309 shares worth $817M.
- Andreas Halvorsen added most to Amazon in Q2 2026, an estimated $629M increase.
- Andreas Halvorsen's biggest Q2 2026 reduction was Tesla, cutting an estimated $774M.
- Andreas Halvorsen fully exited Apple in Q2 2026, selling an estimated $912M.
- Andreas Halvorsen's ten largest holdings make up 36% of its $35.1B portfolio in Q2 2026.
- Andreas Halvorsen opened 34 new positions and closed 21 in Q2 2026.
- Andreas Halvorsen's portfolio value fell 1.9% quarter-over-quarter to $35.1B.
Based on Viking Global Investors's 13F filing for Q2 2026, filed 14 Aug 2026.